Why PacWest Bancorp Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
Gainers
PacWest Bancorp (NASDAQ: PACW) rose 29.9% to $12.66 in pre-market trading after multiple insider buys by Officers, Directors reported late Monday.
Alterity Therapeutics Announced Monday, Granting of New Composition of Matter Patent and Exclusive License Agreement for Assets in Alzheimer’s Disease
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced that the composition of matter patent previously allowed by the United States Patent and Trademark Office (USPTO) has now been granted. The patent, entitled "Compounds for and methods of treating diseases" (No. 11,603,364), covers more than 100 novel compounds with an acyl hydrazone (AH) structure and provides 20 years of exclusivity.
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced the first participant in Italy has been dosed in the Company's Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.
Alterity’s Parkinson’s Candidate Prevents Loss Of Brain Cells In Animal Model
Alterity Therapeutics (NASDAQ:ATHE) announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective…
Here’s Why Alterity Therapeutics Shares Are Moving
Alterity Therapeutics Ltd (NASDAQ: ATHE) shares are trading higher by 5.67% to $4.12 Monday morning after the company announced ATH434 prevents loss of brain cells in Parkinson's Disease animal model.
Alterity Therapeutics Announced Earlier ATH434 Prevents Loss of Brain Cells in Parkinson’s Disease Animal Model
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson's disease (PD).
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial In The United States For The Treatment Of Individuals With Multiple System Atrophy
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrollment at Vanderbilt University Medical Center in Nashville, Tennessee.
Alterity Therapeutics Announced 1-for-10 Reverse ADS Split
Alterity Therapeutics Limited (ASX:ATH, NASDAQ:ATHE) today announced that its Board of Directors approved a ratio change of its American Depository Shares (ADSs) to Ordinary Shares (the "ADS Ratio") from the current ADS Ratio of 1 ADS representing 60 Ordinary Shares to 1 ADS representing 600 Ordinary Shares (the "ADS Ratio Change"). The ADS Ratio Change will be effective on January 9, 2023.